RecruitingNot ApplicableNCT06155916

Sleep and Neuropathic Pain - Intervention Study on Pregabalin

Sleep Structure in Neuropathic Pain Patients, Psychological Factors, Brain Connectivity, and the Effect of Pregabalin on Sleep and Pain


Sponsor

Helsinki University Central Hospital

Enrollment

40 participants

Start Date

Nov 22, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical study is to study sleep and its microstructure in neuropathic pain patients who have or who do not have a clinically significant sleep disturbance, before and during (after 1-month stabile dosage) pregabalin treatment. To find out whether reduced pain by pregabalin associates with improved sleep quality; to study, using resting state fMRI, brain network connectivity and the volume of the choroid plexus before and during pregabalin treatment (after dosage stable for one month) at baseline and during stabile treatment with pregabalin, and to compare the usability and reliability of sleep-related information collected with sleep diaries, actigraphy, iButtons, and ambulatory polysomnography in peripheral painful neuropathy patients. The main questions it aims to answer are: * Is pregabalin more efficacious in neuropathic pain patients who suffer from insomnia compared to those with no clinically meaningful sleep disturbance? * Does sleep disturbance due to pain associate with brain network connectivity and may these changes be reversed by pregabalin treatment? Participants will * Fulfill e-questionnaires and keep sleep diary before and after 1month stabile pregabalin intervention * Before and after 1-month stabile pregabalin medication: 1-week Actiwatch monitoring, iButton (1 day and night), ambulatory polysomnography (1 night), brain fMRI. Researchers will compare patients with high ISI score patients to see if they benefit more from pregabalin treatment than those with low ISI score.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria2

  • Chronic (duration > 3 months) painful peripheral neuropathy
  • Pain moderate to severe (NRS ≥ 4/10) during the past week

Exclusion Criteria2

  • psychotic depression, clinically significant bipolar disorder
  • contraindication for performing brain fMRI (metal in the body etc)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPregabalin

Pregabalin administration and titration to the highest dosage that the patient tolerates. The patient continues with the highest dose for one month and the pre-intervention studies are repeated.


Locations(2)

Helsinki University Central Hospital

Helsinki, HUS, Finland

Helsinki University Hospital, Department of Neurology

Helsinki, Uusimaa, Finland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06155916


Related Trials